Even if vaccinated, individuals with common comorbidities must remain vigilant against SARS-CoV-2 infection, investigators conclude based on analysis of data in the Truveta patient population. “Individuals with immunocompromising conditions and chronic lung disease were most at risk of breakthrough infection, while people with [chronic kidney disease [CKD]) were most at risk of hospitalization following breakthrough infection,” conclude the authors. “Patients with multiple comorbidities have an even greater risk of breakthrough infection or hospitalization compared to patients with none of the studied comorbidities.”
Vaccinated patients were studied for the Jan. 1, 2021, through Mar. 31, 2022, time period. Models described the time from completing the primary vaccination series until breakthrough infection and instances of hospitalization within 14 days of breakthrough infection.
“Of 1,218,630 patients in the Truveta Platform who had completed an initial vaccination sequence between January 1, 2021 and March 31, 2022, 2.85, 3.42, 2.75, and 2.88 percent of patients with CKD, chronic lung disease, diabetes, or [who] are in an immunocompromised state experienced breakthrough infection, respectively, compared to 1.46 percent of the population without any of these four comorbidities,” the investigators report. “We found an increased risk of breakthrough infection and subsequent hospitalization in individuals with any of the four comorbidities when compared to individuals without these four comorbidities.”